CIM vs CSR

Chimera Investment Corporation exhibits severe fundamental weakness, highlighted by a critical Piotroski F-Score of 2/9, indicating poor financial health. While the stock appears undervalued based on a Price/Book of 0.44 and a Graham Number of $34.55, these metrics are likely 'value traps' given the high Debt/Equity ratio of 5.08 and a consistent track record of earnings misses. The technical trend is completely bearish (0/100), and the high dividend yield (13.26%) is precarious given the deteriorating health scores. Overall, the valuation discount is a reflection of systemic risk rather than an opportunity.

CSR exhibits significant fundamental weakness, anchored by a Piotroski F-Score of 4/9 (Stable) and a severe valuation gap where the current price of $66.49 dwarfs both the Graham Number ($31.38) and the Intrinsic Value ($7.14). The company is facing a liquidity crisis with a Quick Ratio of 0.13 and a Current Ratio of 0.44, indicating an inability to cover short-term obligations. Most alarmingly, the dividend payout ratio of 301.96% is unsustainable, suggesting the dividend is being funded by debt or capital reserves rather than earnings. Despite a 'buy' analyst consensus, the combination of stagnant revenue growth (0.30%) and a negative forward P/E makes the current valuation unjustifiable.